Enanta Pharmaceuticals (ENTA) Total Liabilities (2012 - 2026)
Enanta Pharmaceuticals posted quarterly Total Liabilities of $198.1 million for Q1 2026, down 13.66% year-on-year from $229.5 million in Q1 2025, and down 2.36% on a QoQ basis from $202.9 million in Q4 2025.
Enanta Pharmaceuticals (ENTA) has 15 years of Total Liabilities data on file, last reported at $198.1 million in Q1 2026.
- For the quarter ending Q1 2026, Total Liabilities fell 13.66% year-over-year to $198.1 million; the trailing twelve-month figure through Mar 2026 stood at $198.1 million (down 13.66% YoY), and the FY2025 full-year result was $216.0 million, down 12.84% from the prior year.
- Total Liabilities for Q1 2026 stood at $198.1 million, down from $202.9 million in the prior quarter.
- Across five years, Total Liabilities topped out at $257.3 million in Q2 2023 and bottomed at $46.7 million in Q4 2022.
- The 5-year median for Total Liabilities is $221.8 million (2025), against an average of $179.0 million.
- The widest annual swing landed in 2022, when Total Liabilities decreased 16.92%; it then soared 445.34% in 2023.
- A 5-year view of Total Liabilities shows it stood at $46.7 million in 2022, then soared by 406.7% to $236.6 million in 2023, then rose by 0.09% to $236.8 million in 2024, then dropped by 14.32% to $202.9 million in 2025, then declined by 2.36% to $198.1 million in 2026.
- The last three Total Liabilities figures came in at $198.1 million (Q1 2026), $202.9 million (Q4 2025), and $216.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.74 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 731.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 177.22 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 19.51 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 7.12 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 10.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 9.45 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Enanta Pharmaceuticals | 367.22 Mn | 203.44 Mn | - | 198.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 198.12 Mn |
| Dec 31, 2025 | 202.91 Mn |
| Sep 30, 2025 | 216.02 Mn |
| Jun 30, 2025 | 221.75 Mn |
| Mar 31, 2025 | 229.46 Mn |
| Dec 31, 2024 | 236.83 Mn |
| Sep 30, 2024 | 247.84 Mn |
| Jun 30, 2024 | 249.91 Mn |
| Mar 31, 2024 | 247.44 Mn |
| Dec 31, 2023 | 236.62 Mn |
| Sep 30, 2023 | 245.54 Mn |
| Jun 30, 2023 | 257.35 Mn |
| Mar 31, 2023 | 57.07 Mn |
| Dec 31, 2022 | 46.70 Mn |
| Sep 30, 2022 | 54.08 Mn |
| Jun 30, 2022 | 47.19 Mn |
| Mar 31, 2022 | 48.24 Mn |
| Dec 31, 2021 | 56.21 Mn |
| Sep 30, 2021 | 39.36 Mn |
| Jun 30, 2021 | 32.59 Mn |
| Mar 31, 2021 | 31.74 Mn |
| Dec 31, 2020 | 29.02 Mn |
| Sep 30, 2020 | 30.55 Mn |
| Jun 30, 2020 | 31.15 Mn |
| Mar 31, 2020 | 27.51 Mn |
| Dec 31, 2019 | 28.69 Mn |
| Sep 30, 2019 | 27.34 Mn |
| Jun 30, 2019 | 25.39 Mn |
| Mar 31, 2019 | 25.37 Mn |
| Dec 31, 2018 | 27.38 Mn |
| Sep 30, 2018 | 20.55 Mn |
| Jun 30, 2018 | 18.18 Mn |
| Mar 31, 2018 | 21.25 Mn |
| Dec 31, 2017 | 23.14 Mn |
| Sep 30, 2017 | 24.96 Mn |
| Jun 30, 2017 | 14.97 Mn |
| Mar 31, 2017 | 12.95 Mn |
| Dec 31, 2016 | 10.21 Mn |
| Sep 30, 2016 | 11.34 Mn |
| Jun 30, 2016 | 12.93 Mn |
| Mar 31, 2016 | 15.18 Mn |
| Dec 31, 2015 | 14.10 Mn |
| Sep 30, 2015 | 9.86 Mn |
| Jun 30, 2015 | 9.49 Mn |
| Mar 31, 2015 | 21.67 Mn |
| Dec 31, 2014 | 21.71 Mn |
| Sep 30, 2014 | 6.76 Mn |
| Jun 30, 2014 | 6.56 Mn |
| Mar 31, 2014 | 6.63 Mn |
| Dec 31, 2013 | 4.58 Mn |
| Sep 30, 2013 | 6.51 Mn |
| Jun 30, 2013 | 5.26 Mn |
| Mar 31, 2013 | 7.25 Mn |
| Sep 30, 2012 | 995,000.00 |